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Highly selective and rapidly activatable fluorogenic
Thrombin sensors and application in human lung
tissue†
Alicia Megia-Fernandez,a Bethany Mills,b Chesney Michels,b Sunay V. Chankeshwara,a
Kevin Dhaliwalb and Mark Bradley *a,b
A library of FRET-based peptides were prepared and studied as Thrombin substrates. This identified
probes that showed selective activation by Thrombin, low fluorescent background signals, stability to
Factor Xa, matrix metalloproteases, and primary human inflammatory cell lysates and supernatant. These
were selected for further optimization, creating a second generation of fluorogenic probes with improved
solubility and Plasmin resistance. The optimised probe allowed the detection of Thrombin activity in
ex vivo fibrotic human tissue.
Introduction
Optical molecular imaging (OMI) offers a powerful approach
to the real-time measurement of dynamic molecular processes
in diseased tissues. Optical imaging probes1 that only become
fluorescent upon target engagement2–4 or undergo signal
amplification5–7 (e.g. via protease turnover) have many advan-
tages compared to “always-on” probes with respect to signal-
to-noise and limits of detection making them ideal for rapid
point-of-care biochemical measurements.
Thrombin is a serine protease that cleaves soluble fibrino-
gen, with the products subsequently forming insoluble strands
of fibrin, as well as catalysing other coagulation-related reac-
tions, and as such can be considered to be the central orches-
trator of the coagulation cascade.8 Dysregulated Thrombin
activity is implicated in the pathogenesis of multiple
diseases9–11 ranging from thromboembolism, cancer and cor-
onary heart disease and there is strong evidence that
Thrombin plays a critical role in early fibroproliferation,12–15
especially in fibroproproliferative adult respiratory distress syn-
drome (ARDS).16 Indeed, Thrombin activity has been found to
be significantly increased in models of acute lung injury and
in patients with pulmonary fibrosis.17
Measurement of Thrombin activity typically takes advan-
tage of the enzyme’s proteolytic properties with the use of
Förster Resonance Energy Transfer (FRET) substrates, a well-
known and broadly applied strategy in the study of
proteases,18–20 although aptamers have also been used widely
for Thrombin detection.21,22 A key issue with such FRET sub-
strates and their potential in vivo applications is the lack of
selectivity of the probes to the proteases Thrombin and
Plasmin. Typical cleavage sites have been identified by a
Positional Scanning Combinatorial Library approach for
Thrombin and Plasmin, with both displaying a preference for
basic amino acids at P1, with P2-Pro, P3-Xaa and P4-Nle/Leu/
Ile/Phe/Val for Thrombin, and P2-Tyr/Phe/Trp, P3-Xaa and
P4-Lys/Nle/Val/Ile/Phe for Plasmin.23 More recently a consen-
sus recognition sequence for Thrombin identified by phage
display was determined as P2-Pro, P1-Arg, P1′-Ser/Ala/Gly/Thr,
P2′ (not acidic) and P3′-Arg.24
Several activatable cell penetrating peptides with the
sequence DPRSFL derived from the Thrombin substrate pro-
tease-activated receptor-1 (PAR1) and variations (e.g. PPRSFL and
NleTPRSFL) have been used to image Thrombin activity in ather-
osclerotic plaques in arteries25,26 with mice and after brain injury
in rats.27 The extended sequence from PAR1 (P2–P14′) has also
been incorporated into larger constructs (30-mer peptide) to
allow imaging of pulmonary emboli by PET and fluorescence.28
However in the case of Thrombin, due to its pleiotropic
roles29–32 (including amongst others, platelet aggregation, cel-
lular migration, fibrinolysis and peripheral blood cell acti-
vation) and interactions with many target proteins, achieving
substrate selectivity is inherently challenging. In addition
Thrombin and the ubiquitous protease Plasmin found in extra-
cellular matrix and plasma both belong to the family of serine
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proteases that have a requirement for basic amino acids at
the P1 position.
Thus the use of Thrombin activatable imaging probes in
complex biological environments, such as the lung would be
thwarted due to interfering enzymes such as Plasmin and
Factor Xa (possibly at higher concentrations or with far higher
specific activities than Thrombin). The development of tools
for the in vivo analysis of Thrombin thus required the develop-
ment of highly Thrombin specific substrates/probes and
hence, the aim of our work, was to develop a first-in-class
Plasmin resistant and highly selective Thrombin optical probe
for measuring activity in fibrotic human lung tissue.
Results and discussion
Design and synthesis of Thrombin substrates (FRET peptides)
The first set of peptides synthesised were based on a classical
Fluorescein/Methyl Red quenched pair (Fig. 1) with the sub-
strate under investigation located between the fluorophore and
quencher which upon enzymatic cleavage releases the fluoro-
phore with a resultant increase in fluorescence. The peptides
1, 2 and 3 were selected/designed based on recent phage-
display technology,24 and were in good agreement with the
preference for basic amino acids (preferably Arginine) at P1, a
strong preference for Proline at the P2 position, lack of speci-
ficity at P3, and the need for an aliphatic amino acid as P4.23
Other variants (sequences 4–10) were also synthesised and
evaluated, with exchange of Leu, Ile and Nle at P4 envisaged as
a minor change that could affect the interaction of the ali-
phatic amino acid with its hydrophobic binding pocket. All the
peptides were synthesized by manual standard solid-phase
Fmoc chemistry, using aminomethyl-Chemmatrix resin and
DIC/Oxyma as the coupling combination (Scheme 1). Fmoc-Lys
(Dde)-OH was used to allow introduction of Methyl Red
via selective Dde deprotection.33 Following cleavage from
the resin all the compounds were purified by RP-HPLC and
characterized by mass spectrometry (MALDI-TOF; see
Experimental and ESI†).
The FRET efficiency of the probes 1–10 was initially tested
by fluorescence measurements. High quenching of FAM by
MR in the FRET pairing is imperative to ensure low back-
ground fluorescence of the intact probe.
Evaluation of selectivity and specificity of Thrombin substrates
Peptides 1–10 were screened against Thrombin, Plasmin,
Factor Xa and MMP-9 to evaluate the specificity and selectivity
of the peptide substrates (Fig. 2 and Table S1†). Despite high
fold-changes for probes 5, 6, 8 and 9 when incubated with
Thrombin (15, 10, 16 and 10-fold respectively), unacceptable
levels of non-specific probe activation in the presence of
Plasmin were observed for each of these probes (4 to 6-fold
increase in fluorescence signal); rendering them unsuitable.
Probes 1–4, 7 and 10 were each cleaved by Thrombin and
showed moderate increases in fluorescence (2.3 to 7-fold
increase) with lower levels of fluorescence increase in the pres-
ence of Plasmin (<2-fold). Probe 1 was deemed not to be a suit-
able candidate for further investigation due to the high fluo-
rescence background (Fig. S2†).
Fig. 1 Design of Thrombin probes and mode of action. Table 1. Library of peptide probes synthesised for the in vitro analysis of Thrombin (the clea-
vage site is indicated in italics (Nle: Norleucine)). Right: Enzymatic activation of the peptide releases a 5(6)-carboxyfluorescein (FAM) peptide frag-
ment from its proximity to its quencher MethylRed (MR).
Paper Organic & Biomolecular Chemistry
Org. Biomol. Chem. This journal is © The Royal Society of Chemistry 2017
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
8 
A
pr
il 
20
17
. D
ow
nl
oa
de
d 
on
 0
5/
05
/2
01
7 
17
:0
4:
51
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
MALDI-TOF MS analysis following enzymatic treatment
showed that Thrombin cleavage was site specific (X-X-P-R↑G-X-
R-L) for all the sequences tested (see ESI†), while no cleavage
by MMP-9 and Factor Xa was observed for any probe.
As expected some differences in the performance of probes
4, 7 and 10 were observed (Fig. 2, 3 and S1†) following the
exchange of Leu for Ile or Nle at P4, and could be attributed to
the small differences in the aliphatic amino acid side chain
and its interaction with the binding site.
Lung related selectivity studies for the Thrombin probes
Since probes 2, 3, 4, 7 and 10 were shown to be relatively stable
in the presence of Plasmin and had low fluorescence back-
grounds, they were evaluated further in complex biological
environments to assess nonspecific cleavage. The probes were
evaluated with supernatants and lysates of freshly isolated
human neutrophils and human macrophages (Fig. 3) with rela-
tive increases in fluorescence compared for each probe. All
probes (with the exception of 2) were stable under these con-
ditions and demonstrated large increase in fluorescence signal
with Thrombin (3 4-fold; 4 7-fold; 7 3-fold; 10 5.5-fold).
Specific cleavage by Thrombin was confirmed by MALDI-TOF
MS as P-R↑G-V-R-L, although probe 2 demonstrated an
additional cleavage site P-R-G-V↑R-L (Fig. 4), an effect also
observed in other probes containing the motif Val-Arg, such as
probe 8 (Fig. S3†). Plasmin cleavage at the carboxyl side of Lys
and Arg is well recognised34 and was observed with our first
generation probes. The main Plasmin cleavage site was deter-
mined as -P-R-G-W-R↑L- by MALDI-TOF MS analysis of probe
10 following incubation with Plasmin (Fig. 5).
2nd generation of Thrombin probes with Plasmin stability
As some of the probes demonstrated very fast, yet selective,
responses even under exposure to highly oxidative and proteo-
lytic environments such as lysates and supernatants of
primary human leucocytes, increasing aqueous solubility and
gaining greater selectivity over Plasmin was the main goal for
the synthesis of the next generation of Thrombin probes.
Solubility was enhanced by adding polyethylenglycol (PEG2)
units to the peptide 10 which gave good performance in all
previous assays. D-Lysine residues were also incorporated as a
non-natural amino acid to introduce charged/solubilising
groups to improve solubility and at the same time prevent non-
specific protease cleavage. Improvements of selectivity for
Thrombin over Plasmin were envisioned by modifying the key
amino acids involved at the Plasmin cleavage site to their
D-enantiomers. This thus gave probes 11–13 (Fig. 6A).
Scheme 1 Synthesis of Thrombin probes 1–10 by solid-phase syn-
thesis. CM = Chemmatrix resin; DIC = N,N’-diisopropylcarbodiimide;
Fmoc-PEG2-OH = [2-[2-(Fmoc-amino)ethoxy]ethoxy]acetic acid; TFA =
trifluoroacetic acid; TIS = triisopropylsilane.
Fig. 2 Relative increase (fold change) in fluorescence of probes 1–10
(10 µM) after 10 min incubation with either Thrombin (5 U ml−1), Plasmin
(30 nM), Factor Xa (0.5 µM) or MMP-9 (83 kDa, 30 nM), compared to
control (probe in buffer alone (ex/em 485/528 nm)).
Fig. 3 Evaluation of the activation of FRET peptides 2, 3, 4, 7, 10
(10 μM) by Thrombin (5 U ml−1), human neutrophil (huNeu) lysates and
supernatant (sup) and macrophage supernatant (huMac sup). Fold-
changes in fluorescence (ex/em 485/528 nm) compared to probe in
buffer only.
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Evaluation with recombinant Thrombin and Plasmin demon-
strated that these modifications afforded probes that were highly
selective, with increases in fluorescence in response to Thrombin
measured at 15, 15 and 10-fold for probes 11, 12, and 13 respect-
ively within 12 minutes (Fig. 6B), with no increase in fluo-
rescence detected for any probe in the presence of Plasmin.
Due to its high aqueous solubility and Plasmin resistance,
probe 11 was selected as the lead candidate for further investi-
gation. The stability of probe 11 was assessed against a larger
panel of enzymes, known to be highly abundant within fibrotic
tissue (Fig. S4†). None of these, apart from Thrombin, were
able to activate the probe. Moreover, the Km value of 5.4 µM
demonstrated good binding affinity while the turn-over
number of 10.8 s−1 showed good catalysis, with an impressive
kcat/Km value of 1.9 × 10
6 M−1 s−1 obtained for thrombin with
probe 11 in vitro. This is in contrast to kcat/Km values in the
order of 105 M−1 s−1 previously reported for thrombin with
alternative thrombin activated FRET probes.25
Fig. 4 MALDI-TOF MS analysis of peptide 2, demonstrating specific vs. non-specific cleavage by Thrombin and Neutrophils respectively.
Fig. 5 (A) Compound 10 (10 µM) showing Thrombin (5 U ml−1) and Plasmin (30 nM) cleavage while Factor Xa (0.5 µM) did not affect the probe
(ex/em 485/528 nm). (B) Molecular weight of probe 10 and its fragments obtained after enzymatic hydrolysis of shown cleavage sites.
(C) MALDI-TOF MS spectra of probe 10 before and after incubation with the different enzymes (Thrombin cleavage site in green with two fragments
observed at 1074 and 909 Da; Plasmin main cleavage site in red with fragment observed at 1474 Da).
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Validation of Thrombin probes in ex vivo fibrotic lung tissue
As Thrombin is centrally implicated in the fibroproliferative
cascade, the lead optimized probe 11 was evaluated on ex vivo
human lung tissue homogenates from patients with idiopathic
pulmonary fibrosis (IPF) and control non-fibrotic tissue from
the same patients. A significant increase in fluorescence was
detected with probe 11 (1 µM) incubated with fibrotic tissue
homogenates compared to the ‘healthy control’ equivalents
P = 0.0003 (Mann–Whitney test) (Fig. 7A) with specific cleavage
due to Thrombin present within the tissue samples confirmed
by MALDI-TOF MS analysis (Fig. 7B).
Fig. 6 (A) Structure of the second generation Thrombin probes 11–13 with the Thrombin cleavage site in green and the modified Plasmin cleavage
site in red; (B) data showing the relative fold increase of each probe after incubation with Thrombin or Plasmin (ex/em 485/528 nm); (C) the
change in fluorescence provided by probe 11 (10 µM) (excitation/emission 485/528 nm) with recombinant human Thrombin, Plasmin and Factor Xa
(at 5 U ml−1, 30 nM and 0.5 µM respectively); (D) MALDI-TOF MS spectra of 11 showing Thrombin cleavage while Plasmin and Factor Xa did not
significantly affect the probe.
Fig. 7 Addition of probe 11 onto ex vivo human tissue: (A) fluorescence signal generated by the cleavage of probe 11 (1 µM) by human fibrotic
tissue homogenate, control tissue homogenate or recombinant Thrombin (ex/em 485/528 nm); (B) MALDI-TOF MS analysis of probe 11 following
treatment with control human tissue (trace 1) and human fibrotic tissue (trace 2) showing the fragment obtained after specific cleavage by
Thrombin.
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Conclusions
A number of peptide sequences were evaluated as potential
Thrombin substrates with the best sequences selected based
upon activation by Thrombin, stability to Factor Xa, human
inflammatory cell lysates and supernatants. In the second gene-
ration of probes, the inclusion of unnatural D-amino acids at
certain positions within the enzyme cleavable peptide sequence
resulted in the sequence being resilient to cleavage by Plasmin,
whilst still being selectively cleavable by Thrombin.
The lead optimized probe enables the reliable and accurate
detection of Thrombin in tissue samples where other ubiqui-
tous and highly similar proteinases that orchestrate the coagu-
lation cascade are present such as Plasmin and Factor Xa. The
development of a fast and selective probe for Thrombin detec-
tion has utility in a number of fibroproliferative and fibrotic
disorders where Thrombin levels are increased, and has
important implications in the improved diagnosis and thera-
peutic stratification of early stages of diseases characterised by
dysregulated Thrombin activity.
Experimental
Synthesis of the probes
The FRET-peptides were synthesized by standard Fmoc solid-
phase peptide chemistry, with dyes and quenchers coupled
while the probe was on the solid support. After cleavage and
purification by RP-HPLC the compounds 1–13 were character-
ized by MALDI-TOF MS and analytical HPLC. Detailed syn-
thetic procedures and characterization are described in the
ESI.†
MALDI-TOF MS analysis. MALDI spectra were acquired on a
Brüker Ultraflextreme MALDI-TOF MS with a matrix solution
of sinapic acid (10 mg mL−1) in H2O/CH3CN/TFA (50/50/0.1).
Enzyme assays
Enzymatic assays were run in a 384-well format in a PCR
opaque microplate (Thermo Scientific). All experiments were
performed at least in duplicate. Dilutions and reactions were
prepared in MMP buffer (50 mM Tris, 10 mM CaCl2, 0.15 M
NaCl, 0.05% Brij-35, pH 7). Proteolytic activity was determined
by calculating the fold change in fluorescence over background
signal provided by the corresponding dilution of the probe
with exogenous enzymes using a-multiwell plate fluorimeter
(Synergy H1 Hybrid Reader, BioTek instruments Ltd) at
excitation/emission 485/528 nm. Unless otherwise stated, all
probes were investigated at 10 µM. Recombinant human
MMPs (Catalytic domain MMP-1, -2, -3, -7, -8, -9, -10, -11, -12,
-13 (Enzo Life Sciences) and full-length MMP-2, -9, -12 and -13
(Merck/Millipore)) were used at 30 nM. Pro-MMP-13 (R & D
Systems) was activated by incubating with 1 mM 4-amino-
phenylmercuric acetate (APMA) for 2 h at 37 °C. Recombinant
human Thrombin (Sigma-Aldrich, used at 5 U ml−1), Plasmin
(Sigma-Aldrich, used at 30 nM) and Factor Xa (Sigma-Aldrich,
used at 0.5 µM) were used to identify the lead molecular probe
sequences. Human neutrophils and monocytes were isolated
from human blood from healthy volunteers (following
approval of the appropriate regional ethics committee (REC)
and with informed consent of the patients), as previously
described.35 Neutrophil and Macrophage lysate and super-
natant preparation is described within ESI.†
Human tissue supernatant
Human lung tissue was obtained from surgical biopsies for
the investigation of interstitial lung disease (n = 5). Informed
consent was obtained and the study was approved by the
Regional Ethics Committee. Under sterile condition, the tissue
was dissected and stored at −80 °C for further analysis. For the
preparation of tissue supernatant, frozen tissue was suspended
in PBS and homogenised (Bio-Gen PRO200 homogeniser, Pro-
Scientific) on ice. Samples were centrifuged at 13 000 rpm for
15 min at 4 °C and the debris-free supernatant collected. Total
protein concentrations were determined using at Pierce™ BCA
kit (Thermo Scientific). The samples were aliquoted and
stored at −20 °C or −70 °C until further analysis. All tissue
homogenates were investigated at a protein concentration of
333 µg ml−1.
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